Corporate Magazine 2012 - Boehringer Ingelheim

corporate responsibilityperspectives for society11 Unique in Germany: the degree course in pharmaceuticalbiotechnology offered by Biberach University of Applied Sciencein cooperation with industry. Source: HBC/Stefan Sättle2 Simon Fischer, a Biberach University student, graduated with abachelor‘s degree in pharmaceutical biotechnology and alsogained a masters degree in biomedical engineering. Subsequently,he received a stipendium for the cooperative PhD course atBiberach University. He is investigating the effects on growth ofthe Chinese hamster ovary (CHO) cell – the most frequently usedcell in biopharmaceutical production. Source: HBC2Exciting professional fieldsThe interdisciplinarity of research atuniversities and in industry is an importantprecondition for being able todo justice to the future challenges tomedical substances regarding safetyand efficacy at reasonable cost. Pharmaceuticalbiotechnology addressesthe development of strategies for therapid and efficient transfer of the latestmedical and pharmacologicalfindings into safe and efficaciouspharmaceutical products. It thus operateson the dividing line between(bio)chemistry, medicines and biotechnology,thereby bringing togethermany aspects of modern life sciences.Important professional fields, dependingon the choice of focus area,are, for example, in biotechnologicaland pharmaceutical research and industry,in biotechnology, in pharmaceuticalplant construction, in qualitymanagement and in the quality controlfor the pharmaceutical and biotechnologicalindustries.BOEHRINGER INGELHEIM ULM UNIVERSITY BIOCENTER (BIU)Agreed in 2011, the cooperationbetween BoehringerIngelheim and the Universityof Ulm, Germany, has intensified.In a first round in May, a totalof 11 projects was approved.A second round call for applicationsyielded six furtherfunded projects in October.With this the total fundingvolume has been assigned tosix projects in cardiometabolicdiseases, five projects in respiratorydiseases and sixprojects in CNS diseases.All approved projects havebeen initiated.Knowledge transfer between academia and industry37